- Home
- HTH vs SLNO Comparison
HTH vs SLNO Comparison
Compare HTH & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTH | SLNO |
|---|---|---|
| Founded | 1998 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.3B |
| IPO Year | 2003 | 2014 |
Fundamental Metrics
Financial Performance| Metric | HTH | SLNO |
|---|---|---|
| Price | $34.71 | $34.16 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | $37.50 | ★ $108.00 |
| AVG Volume (30 Days) | 314.9K | ★ 1.3M |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | ★ 2.29% | N/A |
| EPS Growth | 51.72 | ★ 108.90 |
| EPS | ★ 2.64 | 0.39 |
| Revenue | ★ $152,188,000.00 | $1,450,788.00 |
| Revenue This Year | N/A | $155.44 |
| Revenue Next Year | $3.07 | $57.99 |
| P/E Ratio | ★ $13.21 | $94.31 |
| Revenue Growth | 15.52 | ★ 138.82 |
| 52 Week Low | $27.35 | $32.63 |
| 52 Week High | $40.41 | $89.12 |
Technical Indicators
Market Signals| Indicator | HTH | SLNO |
|---|---|---|
| Relative Strength Index (RSI) | 31.12 | 32.76 |
| Support Level | $34.27 | $32.63 |
| Resistance Level | $35.69 | $44.60 |
| Average True Range (ATR) | 0.98 | 2.45 |
| MACD | -0.45 | -0.18 |
| Stochastic Oscillator | 1.68 | 14.19 |
Price Performance
Historical ComparisonAbout HTH Hilltop Holdings Inc.
Hilltop Holdings Inc is a Dallas-based financial holding company. The company has three segments: The banking segment includes the operations of the Bank; The broker-dealer segment includes the operations of Securities Holdings,; and the mortgage origination segment is composed of PrimeLending. Majority of revenue is from Broker-dealer Segment.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.